Oxcarbazepine experienced with carbamazepine, toxic epidermal necrolysis, Stevens–Johnson syndrome, and thoughts of suicide. Measurement of serum sodium levels should be considered in maintenance treatment or if symptoms of hyponatremia develop. Low blood sodium is seen in 20-30% of people taking oxcarbazepine and 8-12% of those who have oxcarbazpine-induced hyponatremia experience severe hyponatremia. Some side effects (such as headache) are more pronounced shortly after a dose is taken and tend to fade with the passage of time (60 to 90 minutes). Other side effects include stomach pain, tremor, rash, diarrhea, constipation, decreased appetite and dry mouth. Photosensitivity is a potential side-effect and
Hypotonic hyponatremia a side effect of certain medicines, lung problems such as pneumonia or abscess, brain disease, or certain cancers (most often small cell lung carcinoma). The cornerstone of therapy for SIADH is reduction of water intake. If hyponatremia persists, then demeclocycline (an antibiotic with the side effect of inhibiting ADH) can be used. SIADH can also be treated with specific antagonists of the ADH receptors, such as conivaptan or tolvaptan. Another cause is psychogenic polydipsia. A third group of people with hyponatremia are often said to be "hypervolemic". They are identified by the presence of peripheral edema. In fact, the term